Doximity (DOCS) Outperforms Broader Market: What You Need to Know

In the latest close session, Doximity (DOCS) was up +1.27% at $23.06. This move outpaced the S&P 500's daily gain of 0.44%. Meanwhile, the Dow gained 0.36%, and the Nasdaq, a tech-heavy index, added 0.54%.

The stock of medical social networking site has fallen by 10.14% in the past month, lagging the Medical sector's loss of 4.11% and the S&P 500's loss of 3.31%.

The upcoming earnings release of Doximity will be of great interest to investors. On that day, Doximity is projected to report earnings of $0.28 per share, which would represent a year-over-year decline of 26.32%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $143.67 million, up 3.89% from the year-ago period.

In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $1.54 per share and a revenue of $643.12 million, indicating changes of +8.45% and +12.75%, respectively, from the former year.

Investors should also pay attention to any latest changes in analyst estimates for Doximity. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.

Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.

The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Doximity is holding a Zacks Rank of #4 (Sell) right now.

In the context of valuation, Doximity is at present trading with a Forward P/E ratio of 14.26. This valuation marks a discount compared to its industry average Forward P/E of 19.74.

Investors should also note that DOCS has a PEG ratio of 0.89 right now. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. Medical Info Systems stocks are, on average, holding a PEG ratio of 1.11 based on yesterday's closing prices.

The Medical Info Systems industry is part of the Medical sector. With its current Zacks Industry Rank of 80, this industry ranks in the top 33% of all industries, numbering over 250.

The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.

Radical New Technology Could Hand Investors Huge Gains

Quantum Computing is the next technological revolution, and it could be even more advanced than AI.

While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.

Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power.

Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.

See Top Quantum Stocks Now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Doximity, Inc. (DOCS): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research